Carmenta Bioscience Secures Over $2 Million in Oversubscribed Seed Financing

  Carmenta Bioscience Secures Over $2 Million in Oversubscribed Seed Financing

         Camille Samuels Accepts Seat on Carmenta Board of Directors

Business Wire

PALO ALTO, Calif. -- August 7, 2013

Carmenta Bioscience, Inc., a privately held medical technology company focused
on maternal and fetal health, today announced it has secured over $2M in seed
funding. Proceeds from the financing will support development and
commercialization of a new, proprietary test to better diagnose and predict
preeclampsia in pregnant women. The test is based on a worldwide, exclusive
technology license from Stanford University. Arising in 5-8% of pregnant
mothers, preeclampsia is a leading cause of both preterm birth and maternal
and fetal death.

“We are pleased to count among our financial supporters several influential
members of the life science venture community, the entire Carmenta management
team, the Life Science Angels, as well as noted scientists and physicians
dedicated to improving the lives of mothers and their babies. These funds will
enable Carmenta to demonstrate clinical validity and enable a soft launch of
the test,” said Dr. Matthew Cooper, Carmenta’s President and Chief Executive
Officer. The technology was discovered by Carmenta’s co-founders, Drs. Atul
Butte and Bruce Ling of Stanford University. Their research uncovered a novel
combination of clinically relevant, proprietary protein biomarkers in serum
capable of identifying pregnant mothers with preeclampsia. Carmenta’s test
demonstrated extremely high sensitivity and specificity in an initial trial
funded by the March of Dimes and the SPARK program at Stanford School of
Medicine.

Camille Samuels will join the Carmenta Board of Directors as a result of the
financing. “Cami brings a wealth of knowledge and experience to our board. Her
background makes her ideally suited to guide Carmenta forward as we develop
and prepare to commercialize our diagnostic test for preeclampsia,” commented
Dr. Cooper.

“As a healthcare professional and mother, I am thrilled to join the Carmenta
team. It is exciting to be a part of the confluence of promising technology
and a highly talented team tackling such an important issue in maternal/fetal
health,” stated Ms. Samuels. Ms. Samuels previously served on the Board or as
a Board Observer of other successful diagnostic companies, including ParAllele
BioScience (now Affymetrix; NASDAQ: AFFX) and Genomic Health (NASDAQ: GHDX).

About Carmenta Bioscience

Carmenta Bioscience is a privately held, medical technology company focused on
advancing maternal and fetal health by applying a systems biology approach to
the diagnosis and prediction of preeclampsia. Carmenta’s products in
development combine proprietary computational algorithms with novel serum
protein measurements to classify pregnant mothers at risk for preeclampsia.
For more information regarding Carmenta Bioscience, please
visitwww.carmentabio.com.

Contact:

Carmenta Bioscience, Inc.
Matthew Cooper, 650-308-8544
info@carmentabio.com
 
Press spacebar to pause and continue. Press esc to stop.